Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and its subsidiary GW Pharmaceuticals began construction of its new, state-of-the-art manufacturing plant at Kent Science Park (KSP) in Sittingbourne, UK, with a investment of more than 100 million dollars.
The new facility, expected to be approximately 60,000 square feet, is designed to support both regulatory-approved cannabis-based medicines, such as Epidiolex, and to support the future capacity of new drugs under development.
The new facility will include the installation of animal shelter boxes to promote wildlife in the area and over 1,100 solar panels to provide some of the building’s energy use.
Jazz currently manufactures the extract, active pharmaceutical ingredients and formulated pharmaceuticals at its KSP facility, occupying 12 buildings with over 400 employees, making it, along with the UK, the heart of global cannabinoid manufacturing operations. of the company.
In addition to animal shelter boxes to promote wildlife in the area, the use of single-use plastics will be minimized and over 1,100 solar panels will be installed to provide some of the building’s energy consumption.
“The UK has been our home for more than two decades. This strategic investment underscores Jazz’s continued commitment to the UK and will help us bring potentially life-changing medicines to more patients in desperate need in the UK and around the world.” said Chris ToveyExecutive Vice President, Chief Operating Officer and General Manager of Europe and International at Jazz Pharmaceuticals.
“We are delighted to have started construction of this state-of-the-art facility in Kent, which will create over 100 permanent, highly skilled jobs. This facility, which is due to open in 2024, will not only significantly increase our ability to meet demand growth of our medicines, but helps us maintain our position as the world leader in cannabinoid science,” concluded Tovey.
Photo by Irwan iwe on Unsplash